Articles related to CLINICAL STUDY

Some studies in children have reported a relationship between antidepressant use in pregnancy and neurodevelopment disorders after birth. In this analysis of 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies, crude results suggested up to a doubling in risk of neurodevelopmental outcomes. Significantly, however, no association was observed after balancing for confounding variables.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

Data from the open label Evaluation of NMDA Modulation for Depressive Episodes (EVOLVE) study presented at Psych Congress 2022 showed a significant decrease in HAM-A scores at 1 week, with further decreases in scores observed through 12 months.

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.

Folic acid (B9) prescription in a population of more than 800,000 individuals, yielded a suicide event rate of 4.73 per 100 000 person-months, compared with a rate of 10.61 per 100 000 person-months without folic acid.